Millennium Management
ADCT icon

Millennium Management’s ADC Therapeutics ADCT Stock Holding History

Millennium Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1M Sell
2,899,535
-219,619
-7% -$641K ﹤0.01% 3430
2026
Q1 		$11.7M Buy
3,119,154
+2,790,725
+850% +$11M ﹤0.01% 2029
2025
Q4 		$1.16M Sell
328,429
-373,190
-53% -$1.51M ﹤0.01% 4388
2025
Q3 		$2.81M Buy
701,619
+317,945
+83% +$1M ﹤0.01% 3728
2025
Q2 		$1.03M Buy
383,674
+218,857
+133% +$460K ﹤0.01% 4385
2025
Q1 		$232K Sell
164,817
-246,307
-60% -$419K ﹤0.01% 5229
2024
Q4 		$818K Sell
411,124
-301,277
-42% -$788K ﹤0.01% 4364
2024
Q3 		$2.24M Sell
712,401
-104,055
-13% -$328K ﹤0.01% 3600
2024
Q2 		$2.58M Sell
816,456
-193,981
-19% -$771K ﹤0.01% 3308
2024
Q1 		$4.54M Sell
1,010,437
-1,662,373
-62% -$6.13M ﹤0.01% 2957
2023
Q4 		$4.44M Buy
2,672,810
+22,559
+0.9% +$20.8K ﹤0.01% 2893
2023
Q3 		$2.38M Buy
2,650,251
+1,226,102
+86% +$1.63M ﹤0.01% 3394
2023
Q2 		$3.06M Sell
1,424,149
-369,043
-21% -$830K ﹤0.01% 3122
2023
Q1 		$3.5M Sell
1,793,192
-1,607,928
-47% -$5.93M ﹤0.01% 2928
2022
Q4 		$13.1M Buy
3,401,120
+2,980,867
+709% +$11.9M 0.01% 1850
2022
Q3 		$2.03M Buy
420,253
+362,288
+625% +$2.62M ﹤0.01% 3729
2022
Q2 		$461K Buy
+57,965
New +$548K ﹤0.01% 5022
2022
Q1 		– Sell
-40,367
Closed -$815K – 6832
2021
Q4 		$815K Buy
+40,367
New +$973K ﹤0.01% 4606
2021
Q1 		– Sell
-29,679
Closed -$950K – 5842
2020
Q4 		$950K Sell
29,679
-2,068
-7% -$67.8K ﹤0.01% 3778
2020
Q3 		$1.05M Buy
31,747
+16,860
+113% +$730K ﹤0.01% 3098
2020
Q2 		$697K Buy
+14,887
New +$565K ﹤0.01% 3207

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management's ADCT Position: Q2 2026 in Review

Millennium Management reduced its ADC Therapeutics (ADCT) stake by 7% in Q2 2026, selling an estimated $641K and leaving 2,899,535 shares worth $3.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3430.

Millennium Management first reported a position in ADCT in Q2 2020 and has held it in 21 quarters since. The position peaked at $13.1M in Q4 2022. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Millennium Management held 2,899,535 shares of ADC Therapeutics worth $3.1M as of Q2 2026.
  • Millennium Management sold 219,619 ADC Therapeutics shares in Q2 2026, an estimated $641K.
  • ADC Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q2 2026, its #3430 holding.
  • Millennium Management first reported a position in ADC Therapeutics in Q2 2020 and has held it in 21 quarters since.
  • Millennium Management's ADC Therapeutics position peaked at $13.1M in Q4 2022.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.